Companies › Guangzhou Patronus Biotech
2 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 2; Infectious disease, Vaccines; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LYB004 Recombinant varicella zoster virus glycoprotein E (VZV-gE) vaccine adjuvanted with A01B or | VZV | Phase 2 | Herpes Zoster (HZ); Herpes Zoster | Dec 2026 |
| LYB005 Recombinant Respiratory Syncytial Virus (RSV) vaccine | – | Phase 2 | Respiratory Syncytial Virus Infection Prevention; Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus Infection | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06335849 | LYB004 | Phase 1 | Herpes Zoster | Infectious disease | Sep 2025 |
| NCT06442241 | LYB005 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Dec 2025 |
| NCT06874842 | LYB004 | Phase 1 | Herpes Zoster (HZ) | Infectious disease | Feb 2026 |
| NCT06904222 | LYB005 | Phase 1 | Respiratory Syncytial Virus Infection | Infectious disease | Aug 2026 |
| NCT07311148 | LYB004 | Phase 2 | Herpes Zoster (HZ) | Vaccines | Dec 2026 |
| NCT07208461 | LYB005 | Phase 2 | Respiratory Syncytial Virus Infection Prevention | Infectious disease | Dec 2026 |
Green Cross Aribio Lab Dynavax Technologies Osivax Artcline
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.